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BACKGROUND
Information regarding the safety and efficacy of artemisinin combination treatments for 
malaria in pregnant women is limited, particularly among women who live in sub-Saharan 
Africa.
METHODS
We conducted a multicenter, randomized, open-label trial of treatments for malaria in preg-
nant women in four African countries. A total of 3428 pregnant women in the second or third 
trimester who had falciparum malaria (at any parasite density and regardless of symptoms) 
were treated with artemether–lumefantrine, amodiaquine–artesunate, mefloquine–artesu-
nate, or dihydroartemisinin–piperaquine. The primary end points were the polymerase-chain-
reaction (PCR)–adjusted cure rates (i.e., cure of the original infection; new infections during 
follow-up were not considered to be treatment failures) at day 63 and safety outcomes.
RESULTS
The PCR-adjusted cure rates in the per-protocol analysis were 94.8% in the artemether–lume-
fantrine group, 98.5% in the amodiaquine–artesunate group, 99.2% in the dihydroartemis-
inin–piperaquine group, and 96.8% in the mefloquine–artesunate group; the PCR-adjusted 
cure rates in the intention-to-treat analysis were 94.2%, 96.9%, 98.0%, and 95.5%, respec-
tively. There was no significant difference among the amodiaquine–artesunate group, dihy-
droartemisinin–piperaquine group, and the mefloquine–artesunate group. The cure rate in 
the artemether–lumefantrine group was significantly lower than that in the other three 
groups, although the absolute difference was within the 5-percentage-point margin for 
equivalence. The unadjusted cure rates, used as a measure of the post-treatment prophylactic 
effect, were significantly lower in the artemether–lumefantrine group (52.5%) than in groups 
that received amodiaquine–artesunate (82.3%), dihydroartemisinin–piperaquine (86.9%), or 
mefloquine–artesunate (73.8%). No significant difference in the rate of serious adverse 
events and in birth outcomes was found among the treatment groups. Drug-related adverse 
events such as asthenia, poor appetite, dizziness, nausea, and vomiting occurred signifi-
cantly more frequently in the mefloquine–artesunate group (50.6%) and the amodiaquine–
artesunate group (48.5%) than in the dihydroartemisinin–piperaquine group (20.6%) and the 
artemether–lumefantrine group (11.5%) (P<0.001 for comparison among the four groups).
CONCLUSIONS
Artemether–lumefantrine was associated with the fewest adverse effects and with ac-
ceptable cure rates but provided the shortest post-treatment prophylaxis, whereas dihy-
droartemisinin–piperaquine had the best efficacy and an acceptable safety profile. 
(Funded by the European and Developing Countries Clinical Trials Partnership and 
others; ClinicalTrials.gov number, NCT00852423.)
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Malaria during pregnancy is a major public health problem in coun-tries where the disease is endemic.1 In 
areas in which the intensity of transmission is 
moderate to high and does not vary substan-
tially from year to year, most malaria infections 
during pregnancy remain asymptomatic but in-
crease the risk of maternal anemia and low birth 
weight, the latter of which is associated with 
increased infant mortality.2 In areas where the 
intensity of transmission is low and varies sub-
stantially between years, symptomatic malaria 
and severe disease can develop in pregnant 
women, with an associated increased risk of 
fetal loss and maternal death.2 Considering the 
harmful effects of malaria during pregnancy, it 
is extremely important to treat the disease ade-
quately with efficacious medicines. However, 
little information is available regarding the 
pharmacokinetics, safety, and efficacy of new 
antimalarial agents in pregnant women3-5 because 
pregnant women are systematically excluded from 
regulatory trials.
For women in the second or third trimester 
of pregnancy, World Health Organization (WHO) 
guidelines recommend a 3-day course with ei-
ther an artemisinin-based combination therapy 
that is known to be effective in the country or 
region or clindamycin plus a 7-day course of 
either artesunate or quinine.6 Although the expe-
rience regarding the use of artemisinin-based 
combination therapies in pregnancy is increas-
ing,6 this information is still limited, particularly 
in sub-Saharan Africa.
Me thods
Trial Design
We conducted this randomized, open-label trial 
from June 2010 through August 2013 at seven 
sites in four sub-Saharan African countries: 
Burkina Faso (two sites), Ghana (three), Malawi 
(one), and Zambia (one). The trial protocol, 
which is available with the full text of this article 
at NEJM.org, has been described in detail else-
where.7 In brief, pregnant women in the second 
or third trimester who had a Plasmodium falci-
parum monoinfection of any density, regardless 
of symptoms, a hemoglobin level of 7 g per deci-
liter or more, and no other serious illness were 
recruited into the trial and randomly assigned to 
one of the following four treatments: artemether–
lumefantrine, amodiaquine–artesunate, meflo-
quine–artesunate, or dihydroartemisinin–piper-
aquine.
Sigma-Tau Industrie Farmaceutiche Riunite 
donated dihydroartemisinin–piperaquine, Novar-
tis donated artemether–lumefantrine, and Sanofi-
Aventis donated artesunate–amodiaquine. The 
Drugs for Neglected Diseases Initiative facilitat-
ed the negotiation for the procurement of arte-
sunate–mefloquine from Farmanguinhos, which 
donated the treatment. The donors did not have 
any role in reviewing the protocol or the manu-
script, although the protocol synopsis was pro-
vided to the manufacturers.
The trial was set up in a pragmatic approach 
with three treatment groups per country with 
the use of a balanced, incomplete block design, 
which allowed for the maximized use of re-
sources and took into account the policies re-
garding antimalarial treatment in the respective 
countries (Table S1 in the Supplementary Ap-
pendix, available at NEJM.org). All doses of the 
study drugs were given under direct observation 
on days 0, 1, and 2 and according to the recom-
mendations of the manufacturer (Table S2 in the 
Supplementary Appendix). At recruitment, the 
gestational age was estimated with the use of 
the symphysiofundal height, and the fetal viabil-
ity was assessed by means of ultrasonography 
with a portable multipurpose machine.
Follow-up
After completion of the 3-day treatment, patients 
were asked to return to the clinic (in Ghana, 
patients were visited at home) for follow-up visits 
on days 3 and 7 and then once every week until 
day 63. At each visit, a medical history was ob-
tained, and information was collected regarding 
current signs and symptoms, including the start 
and end date, the severity (mild, moderate, se-
vere, or life-threatening), and the perceived rela-
tionship to the study treatment (definitely unre-
lated, unlikely to be related, possibly related, 
probably related, or definitely related), as well as 
the outcome of any adverse events. A blood sam-
ple was obtained for malaria smears and dried 
blood spots for later genotyping, for full blood 
counts (on days 7, 14, 28, and 63 only), and for 
measurement of the total bilirubin, alanine amino-
transferase, and creatinine levels (on days 7 and 
14 only). Rescue treatment for recurrent infec-
tion was given according to national guidelines.
A Quick Take 
is available at 
NEJM.org
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At the end of the active follow-up period, 
women were asked to attend the antenatal clinic 
monthly or when they felt unhealthy, until deliv-
ery. After delivery, the newborn was examined 
for congenital malformations and weighed, and 
the gestational age was estimated with the use 
of the total Ballard score (range, −10 [20 weeks 
of gestation] to 50 [44 weeks of gestation]).8 A 
placental-biopsy specimen was obtained as soon 
as possible after delivery and was preserved in 
10% neutral buffered formalin. The biopsy spec-
imens were processed and embedded in paraffin 
wax by means of standard techniques and were 
kept at 4°C. Paraffin sections that were 4 mm 
thick were stained with hematoxylin and eosin 
and read at the Barcelona Center for Interna-
tional Health Research.7
Laboratory Procedures
Giemsa-stained thick and thin blood films were 
read independently by two readers. Blood smears 
with discordant results (differences between the 
two microscopists with regard to the diagnosis 
of the species, positivity, or parasite density of 
>50%) were reexamined by a third, independent 
microscopist, and parasite density was calculat-
ed by averaging the two closest counts. We esti-
mated parasite density by counting the number 
of asexual parasites per 200 white cells, assum-
ing a white-cell count of 8000 per cubic milli-
meter. The total bilirubin, alanine aminotrans-
ferase, and creatinine levels were measured with 
the use of the Flexor Junior biochemistry ana-
lyzer. The full blood count was obtained with 
the use of the Sysmex XT-2000i hematology ana-
lyzer. The hemoglobin level was measured with 
the use of the HemoCue system. For polymerase-
chain-reaction (PCR) analysis, blood samples 
were collected on filter papers (Whatman 3MM) 
that were subsequently transported to the Insti-
tute of Tropical Medicine, Antwerp, Belgium, 
where centralized genotyping (of the glutamate-
rich protein [GLURP] and surface proteins of the 
P. falciparum merozoite [MSP2 and MSP1]) was 
performed to distinguish reinfection from recru-
descence.9 Samples that did not produce a result 
were classified as indeterminate.
Trial End Points
The primary end points of the trial were the 
PCR-adjusted cure rates at day 63 (Table S3 in 
the Supplementary Appendix) and the safety 
outcomes7 (Table S4 in the Supplementary Ap-
pendix). In the estimation of the PCR-adjusted 
cure rate, only recurrent infections that were 
shown by means of genotyping to be the same 
infections as those before treatment (i.e., recru-
descent infections) were considered to be treat-
ment failures; conversely, for the estimation of 
the PCR-unadjusted cure rate, all recurrent infec-
tions were considered to be treatment failures.
Treatment failures were classified as either 
early or late treatment failures, with the latter 
category comprising late clinical failures and 
late parasitologic failures. Early treatment failure 
was defined as one of the following: the devel-
opment of danger signs or severe malaria or 
worsening of clinical conditions on day 0, 1, 2, 
or 3 in the presence of parasitemia; parasitemia 
on day 3 that was the same as or greater than 
the count on day 0; or parasitemia on day 3 and 
fever (axillary temperature, ≥37.5°C). Late clini-
cal failure was defined as the either the develop-
ment of danger signs or severe malaria or wors-
ening of clinical conditions on any day after day 
3 in the presence of parasitemia, without the 
patient having previously met any of the criteria 
for early treatment failure, or the presence of 
parasitemia and fever on any day after day 3, 
without the patient having previously met the 
criteria for early treatment failure. Late parasito-
logic failure was defined as the presence of 
parasitemia after day 3 and an axillary tempera-
ture of less than 37.5ºC, without the patient hav-
ing previously met any of the criteria of early 
treatment failure or late parasitologic failure. An 
adequate clinical and parasitologic response was 
defined as the absence of parasitemia at the end 
of follow-up (day 63), regardless of the axillary 
temperature, without the patient having previ-
ously met any of the criteria of early treatment 
failure or late treatment failure.
Adverse events and serious adverse events 
were recorded and monitored throughout the 
trial by an independent data and safety monitor-
ing board. The relationship between treatment 
and adverse events or serious adverse events was 
determined by the local investigator on the basis 
of clinical judgment, possible alternative causes 
(e.g., concomitant therapy), time of occurrence 
relative to the study treatment, and available 
information on the study treatment. The data 
and safety monitoring board reviewed listings of 
serious adverse events regularly. Secondary end 
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points were PCR-unadjusted cure rates (Table S3 
in the Supplementary Appendix) at day 63, time 
to treatment failure (PCR-adjusted and PCR-
unadjusted) (Fig. S1 in the Supplementary Ap-
pendix), asexual parasite clearance,10 gametocy-
temia (prevalence and density), and changes in 
the hemoglobin level.
Trial Oversight
The contributions of the authors are listed in 
Table S5 in the Supplementary Appendix. The 
authors vouch for the accuracy and completeness 
of the data and for the fidelity of the trial to the 
protocol. The trial was approved by the ethics 
committee at the Antwerp University Hospital, 
the relevant national or local ethics committees, 
and the national drug regulatory authorities 
(Table S6 in the Supplementary Appendix). All 
the study participants provided written informed 
consent. If the woman was illiterate, she would 
provide a fingerprint and a witness would write 
the name of the patient onto the form and sign 
and date it.
Statistical Analysis
The trial was designed to determine whether all 
four treatments had similar PCR-adjusted cure 
rates (difference, <5 percentage points), with 
95% power for each of the six pairwise compari-
sons and 80% power for the combined hypothesis 
that all the treatments would be equivalent.7 No 
multiplicity adjustment for the primary analysis 
was performed because the four treatments would 
be declared similar only if all six pairwise com-
parisons were shown to be within the 5-percent-
age-point margin. For this joint decision rule, no 
alpha-level correction was needed.11
Data were captured in an electronic case-
report form that was developed with the use of 
MACRO software (Infermed). A statistical analy-
sis plan was developed before the database lock. 
For the primary end point, three analysis popu-
lations were used: a per-protocol population, an 
intention-to-treat population that excluded pa-
tients who were lost to follow-up or withdrew 
and those with missing or indeterminate results 
on PCR assay, and an intention-to-treat popula-
tion that included multiple imputations of data 
from women who were lost to follow-up or with-
drew and from those who had missing or inde-
terminate results on PCR assay. The per-protocol 
analysis was considered to be the primary analy-
sis approach. Persons with major protocol viola-
tions, defined as a violation of the inclusion or 
exclusion criteria, receipt of a treatment different 
from the randomly assigned one, missing at least 
a full day of treatment, intake of other drugs with 
antimalarial activity, and missing day 63 blood 
smears, were excluded from the per-protocol 
analysis. All the secondary end points were ana-
lyzed with the use of an available-data approach.
We tested the primary hypothesis by calculat-
ing the 95% confidence interval for the differ-
ence in cure rates. If the difference in true (PCR-
adjusted) cure rates was less than 5 percentage 
points, the treatments were considered to be 
therapeutically equivalent. This margin was cho-
sen on the basis of the WHO recommendation 
that a new recommended antimalarial treatment 
that is adopted as policy should have an average 
cure rate of 95% or more as assessed in clinical 
trials. The confidence interval was calculated 
from a generalized linear model with adjustment 
for differences among the four countries. A num-
ber of sensitivity analyses were performed, in-
cluding an analysis with multiple imputation of 
missing outcomes, a pairwise comparison that 
was limited to trial sites where a head-to-head 
comparison of treatments was performed, an 
analysis with adjustment for parasite density, 
gestational age, and gravidity at trial entry, and 
an analysis of the time to treatment failure with 
the use of Cox regression models. For the safety 
analysis, all the women who received at least one 
dose of the study treatment were included. De-
tails of the subgroup analyses are provided in 
the Supplementary Appendix.
R esult s
Participants
A total of 3428 pregnant women who had P. falci-
parum infection were randomly assigned to receive 
one of four treatment: artemether–lumefantrine 
(881 women), amodiaquine–artesunate (843), di-
hydroartemisinin–piperaquine (855), or meflo-
quine–artesunate (849) (Fig. 1). The trial sites in 
Burkina Faso recruited 870 women, those in 
Ghana 788, the one in Malawi 870, and the one 
in Zambia 900. Five women were withdrawn by 
the investigators immediately after starting the 
treatment because of protocol deviations (3 did 
not have malaria, 1 was not pregnant, and 1 had 
been enrolled previously), although they were 
included in the safety analysis.
The intention-to-treat analysis included 3150 
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women (830 women in the artemether–lumefan-
trine group, 791 in the amodiaquine–artesunate 
group, 759 in the dihydroartemisinin–pipera-
quine group, and 770 in the mefloquine–artesu-
nate group). The per-protocol analysis included 
3000 women (810 women in the artemether–
lumefantrine group, 742 in the amodiaquine–
artesunate group, 720 in the dihydroartemis-
inin–piperaquine group, and 728 in the 
mefloquine–artesunate group) (Fig. 1). Approxi-
mately half the exclusions from the per-protocol 
analysis (227 of 423 women [53.7%]) were due to 
loss to follow-up, withdrawal, or death.
The characteristics of the participants at base-
line were similar among the treatment groups 
(Table 1). Most women were included during the 
second trimester of pregnancy, and primigravi-
dae represented approximately one third of the 
trial population. Parasite density was more than 
2000 per cubic milliliter in approximately one 
Figure 1. Randomization of Patients and the Analysis Populations.
A total of five women were excluded after the receipt of the first dose of study medication because of entry-criteria violations. The exclu-
sions from the intention-to-treat population (blue) and the per-protocol population (yellow-green) are based on the efficacy population. 
The intention-to-treat population excluded women who were lost to follow-up, died, withdrew, or had missing or indeterminate results 
on polymerase-chain-reaction assay; however, these women were included in the intention-to-treat analyses that used multiple imputa-
tions. The per-protocol population also excluded persons with major protocol violations, defined as a violation of the inclusion or exclu-
sion criteria, receipt of a treatment different from the randomly assigned one, missing at least a full day of treatment, intake of other 
drugs with antimalarial activity, and missing day 63 blood smears.
8358 Patients were assessed for eligibility
3428 Were enrolled and underwent
randomization
855 Were assigned to receive
dihydroartemisinin–piperaquine
and included in safety
population
849 Were assigned to receive
mefloquine–artesunate
and included in safety
population
853 Were included in efficacy
population
848 Were included in efficacy
population
881 Were assigned to receive
artemether–lumefantrine
and included in safety
population
843 Were assigned to receive
amodiaquine–artesunate
and included in safety
population
1 Was excluded after
first dose
1 Was excluded after
first dose
2 Were excluded after
first dose
1 Was excluded after
first dose
880 Were included in efficacy
population
842 Were included in efficacy
population
759 Were included in intention-
to-treat population
770 Were included in intention-
to-treat population
50 Were excluded 51 Were excluded 94 Were excluded 78 Were excluded
830 Were included in intention-
to-treat population
791 Were included in intention-
to-treat population
720 Were included in
per-protocol population
728 Were included in
per-protocol population
2 Did not meet
inclusion 
criteria
15 Had treatment
violation
53 Had follow-up
violation
3 Did not meet
inclusion 
criteria
3 Met exclusion
criteria
34 Had treatment
violation
60 Had follow-up
violation
1 Did not meet
inclusion 
criteria
2 Met exclusion
criteria
36 Had treatment
violation
94 Had follow-up
violation
6 Did not meet
inclusion 
criteria
1 Met exclusion
criteria
26 Had treatment
violation
87 Had follow-up
violation
810 Were included in
per-protocol population
742 Were included in
per-protocol population
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third of the women, and few women (6.1%) had 
fever at the time of recruitment.
Treatment Efficacy
The large majority of treatment failures were late 
parasitologic failures, with fewer women having 
a late clinical failure (Table 2). Most cases of late 
treatment failures were classified as new infec-
tions.
According to the per-protocol analysis, the 
overall PCR-adjusted cure rate at day 63 was 
94.8% (95% confidence interval [CI], 93.0 to 
Characteristic
Artemether– 
Lumefantrine 
(N = 880)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 853)
Mefloquine– 
Artesunate 
(N = 848)
Country (no.)
Burkina Faso 290 291 0 288
Ghana 0 261 265 260
Malawi 290 290 288 0
Zambia 300 0 300 300
Age (yr) 22.6±5.6 23.4±5.9 22.3±5.4 23.5±5.9
Symptomatic malaria (%)† 37.2 34.9 37.4 43.8
Fever (%) 6.5 6.8 3.2 8.0
Parasite density >2000/mm3 (%) 30.6 25.3 29.1 32.1
≥3 symptoms (%)‡ 7.2 9.3 11.8 14.3
Gametocytes present (%) 2.4 2.9 2.5 0.7
Parasite density (per mm3)
Median 800 569 680 840
Interquartile range 213–2880 165–2025 200–2760 218–3040
Hemoglobin (g/dl)
Median 10.2 10.1 10.1 10.1
Interquartile range 9.2–11.0 9.1–11.0 9.1–11.0 9.1–10.9
Gravidity (%)
1 36.3 37.4 40.0 32.7
2 23.1 22.2 25.3 23.7
≥3 40.6 40.4 34.7 43.6
Trimester of gestation (%)§
Second 71.8 75.0 68.5 65.8
Third 28.2 24.9 31.5 34.2
Bed net used before trial entry (%) 34.4 34.6 27.9 37.5
Insecticide-treated bed net used before 
trial entry (%)¶
24.8 23.9 17.1 27.9
Use of intermittent preventive treatment 
before day 0 (%)
9.9 10.9 13.7 16.4
*  Plus–minus values are means ±SD. There were no significant differences at baseline among the treatment groups.
†  Symptomatic malaria was defined as any of the following: fever (axillary temperature, ≥37.5°C) at baseline with parasit-
emia of any density; a parasite count of more than 2000 per cubic millimeter, regardless of symptoms; or at least three 
of the following symptoms — fever in the previous 24 hours, weakness or fatigue, muscle or joint aches, headache, or 
convulsion — with parasitemia of any density.
‡  Symptoms included fever in the previous 24 hours, weakness or fatigue, muscle or joint aches, or headache.
§  One woman in the amodiaquine–artesunate group was included in the trial during the first trimester of pregnancy.
¶  Women were provided with an insecticide-treated bed net at the start of the trial.
Table 1. Characteristics of the Participants at Baseline.*
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96.1; 748 of 789 women) in the artemether–
lumefantrine group, 98.5% (95% CI, 97.3 to 99.2; 
718 of 729 women) in the amodiaquine–artesu-
nate group, 99.2% (95% CI, 98.2 to 99.6; 701 of 
707 women) in the dihydroartemisinin–pipera-
quine group, and 96.8% (95% CI, 95.2 to 97.9; 
693 of 716 women) in the mefloquine–artesu-
nate group (Table 2, and Fig. S1 in the Supple-
mentary Appendix). There was no significant 
difference among the amodiaquine–artesunate 
group, the dihydroartemisinin–piperaquine group, 
and the mefloquine–artesunate group. The cure 
rate in the artemether–lumefantrine group was 
significantly lower than the rate in the other 
three treatment groups (P<0.001), although the 
difference was within the prespecified margin of 
5 percentage points (Fig. 2).
The unadjusted cure rates (Table S3 in the 
Supplementary Appendix) were significantly low-
er in the artemether–lumefantrine group (52.5%; 
425 of 810 women) than in the amodiaquine–
artesunate group (82.3%; 611 of 742), the dihy-
droartemisinin–piperaquine group (86.9%; 626 
of 720), and the mefloquine–artesunate group 
(73.8%; 537 of 728) (P<0.001) (Table 2). Country-
specific results are provided in Table S7 in the 
Supplementary Appendix. The intention-to-treat 
analyses and analyses with multiple imputations 
of unavailable outcomes further supported the 
efficacy results (Table S8 in the Supplementary 
Appendix). Results from the sensitivity analyses 
were generally consistent with those from the 
primary analyses.
At day 2 after the initiation of treatment, 
nearly all the women (>99.5%) had a negative 
blood smear. However, parasite clearance was 
slower among the women treated with arte-
mether–lumefantrine than among women treat-
ed with the other therapies; at day 1 after the 
start of treatment, 24.8% of the women (217 of 
875 women) in the artemether–lumefantrine group 
still had detectable parasitemia, as compared 
with 6.9% (57 of 828) in the amodiaquine–arte-
sunate group, 8.0% (67 of 837) in the dihydro-
artemisinin–piperaquine group, and 13.5% (113 
of 837) in the mefloquine–artesunate group 
(P<0.001).
Gametocyte prevalence at enrollment was low 
(Table 1), with a median density between 11 and 
40 gametocytes per cubic millimeter. Gameto-
cyte carriage remained low throughout follow-up, 
with no significant difference among the treat-
ment groups. Similarly, changes in the hemoglo-
bin level did not differ significantly among the 
treatment groups throughout follow-up (Fig. S2 
in the Supplementary Appendix).
The prevalence of placental malaria infection 
at delivery was similar among the treatment 
groups (P = 0.47). The mean birth weight of the 
babies, after adjustment according to country, 
was similar among the treatment groups. The 
mean (±SD) birth weight was 2854±449 g in the 
artemether–lumefantrine group, 2880±452 g in 
the amodiaquine–artesunate group, 2901±454 g 
in the dihydroartemisinin–piperaquine group, 
and 2875±433 g in the mefloquine–artesunate 
group (P = 0.40). Similarly, the percentage of 
babies with low birth weight did not vary sig-
nificantly among the treatment groups (17.2% in 
the artemether–lumefantrine group, 15.5% in the 
amodiaquine–artesunate group, 14.1% in the 
dihydroartemisinin–piperaquine group, and 15.2% 
in the mefloquine–artesunate group; P = 0.32).
Safety
A total of 72 women had serious adverse events 
during the 63-day follow-up, including 1 woman 
in the mefloquine–artesunate group who died 
approximately 1 month after treatment, probably 
from meningitis (Table S9 in the Supplementary 
Appendix). There were 10 serious adverse events 
that were assessed by the site investigator as be-
ing probably related to the study medication, 
including 5 in the amodiaquine–artesunate 
group (anemia in 2 women, upper abdominal 
pain in 1, and malaise in 2), 4 in the meflo-
quine–artesunate group (abdominal pain in 1, 
vomiting in 2, and malaise in 1), and 1 in the 
dihydroartemisinin–piperaquine group (a possi-
ble adverse drug reaction with headache and 
general weakness 2 days after the completion of 
treatment; the woman recovered completely). No 
significant difference in the occurrence of seri-
ous adverse events was found among the treat-
ment groups.
Women treated with mefloquine–artesunate 
and those treated with amodiaquine–artesunate 
had a significantly higher incidence of any ad-
verse event (84.9% [722 of 850 women] and 
79.0% [665 of 842], respectively) than did those 
in the artemether–lumefantrine group (72.8%; 
641 of 881) and those in the dihydroartemisinin–
piperaquine group (70.4%; 602 of 855) (P<0.001 
for the comparison among the four groups) 
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(Table 3). Adverse events that were related to the 
treatment, as determined by the investigators, 
occurred significantly more frequently in the 
mefloquine–artesunate group (in 50.6% of women; 
430 of 850 women) and the amodiaquine–arte-
sunate group (in 48.5%; 408 of 842) than in the 
dihydroartemisinin–piperaquine group (in 20.6%; 
176 of 855) and the artemether–lumefantrine 
group (in 11.5%; 101 of 881) (P<0.001 for the 
comparison among the four groups). This result 
was due mainly to the higher occurrence of 
asthenia, poor appetite, dizziness, nausea, and 
vomiting among women treated with meflo-
quine–artesunate or amodiaquine–artesunate 
than among those treated with dihydroartemis-
inin–piperaquine or artemether–lumefantrine 
(Table 3).
Behavioral changes were observed in 4 women, 
of whom 2 were in the amodiaquine–artesunate 
group (changes noted on day 2 and day 3 after 
treatment), 1 was in the mefloquine–artesunate 
group (changes noted on day 2 after treatment), 
and 1 was in the artemether–lumefantrine group 
(changes noted on day 60 after treatment); the 
two behavioral changes in the amodiaquine–
artesunate group were considered by the site 
investigator to be possibly related to treatment. 
All the women recovered completely. A woman 
Variable
Artemether– 
Lumefantrine 
(N = 880)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 853)
Mefloquine– 
Artesunate 
(N = 848)
Efficacy outcome — no. (%)†
Early treatment failure 0 2 (0.2) 1 (0.1) 0
Development of danger signs or severe 
malaria
0 0 1 (0.1) 0
Rescue treatment on any of days 0–3 0 1 (0.1) 0 0
Parasitemia on day 3 ≥ day 0 0 1 (0.1) 0 0
Late clinical failure 26 (3.0) 13 (1.5) 6 (0.7) 28 (3.3)
Recrudescence 4 (0.5) 2 (0.2) 1 (0.1) 8 (0.9)
New infection 21 (2.4) 10 (1.2) 5 (0.6) 18 (2.1)
Indeterminate or sample unavailable 1 (0.1) 1 (0.1) 0 2 (0.2)
Late parasitologic failure 362 (41.1) 123 (14.6) 91 (10.7) 176 (20.8)
Recrudescence 37 (4.2) 9 (1.1) 5 (0.6) 17 (2.0)
New infection 303 (34.4) 100 (11.9) 71 (8.3) 144 (17.0)
Indeterminate or sample unavailable 22 (2.5) 14 (1.7) 15 (1.8) 15 (1.8)
Adequate clinical and parasitologic response 436 (49.5) 642 (76.2) 653 (76.6) 557 (65.7)
Response could not be determined 56 (6.4) 62 (7.4) 102 (12.0) 87 (10.3)
Received rescue treatment but had no 
infection
6 (0.7) 11 (1.3) 8 (0.9) 9 (1.1)
Died‡ 0 0 0 1 (0.1)
Lost to follow-up or withdrew 50 (5.7) 51 (6.1) 94 (11.0) 77 (9.1)
Treatment success§
Per-protocol analysis
PCR-adjusted
No. of patients 789 729 707 716
Rate — % (95% CI) 94.8 (93.0–96.1) 98.5 (97.3–99.2) 99.2 (98.2–99.6) 96.8 (95.2–97.9)
PCR-unadjusted
No. of patients 810 742 720 728
Rate — % (95% CI) 52.5 (49.0–55.9) 82.3 (79.4–84.9) 86.9 (84.3–89.2) 73.8 (70.4–76.8)
Table 2. Efficacy Outcomes and Treatment Success Rates.*
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treated with amodiaquine–artesunate reported 
hallucinations on day 3 after treatment; these 
were considered by the investigator to be possi-
bly related to treatment. The woman recovered 
completely. Significantly more women in the 
amodiaquine–artesunate group than in the other 
three groups reported insomnia: 4.0% (34 of 
842 women) in the amodiaquine–artesunate group 
versus 2.5% (21 of 850) in the mefloquine–arte-
sunate group, 1.6% (14 of 855) in the dihydroar-
temisinin–piperaquine group, and 0.3% (3 of 881) 
in the artemether–lumefantrine group (P = 0.04).
The pulse rate and blood pressure tended to be 
lower among women treated with amodiaquine–
artesunate than among those in the other three 
groups (Figs. S3 and S4 in the Supplementary 
Appendix). The percentage of women with a dia-
stolic blood pressure of less than 50 mm Hg and 
a systolic blood pressure of less than 90 mm Hg 
was higher in the amodiaquine–artesunate group 
than in the other groups (P<0.001). Similarly, 
the percentage of women with a pulse rate of 
less than 60 beats per minute appeared to be 
higher in the amodiaquine–artesunate group 
than in the other groups, but this difference was 
not significant (P = 0.40). Hypotension or a low 
diastolic blood pressure as an adverse event (i.e., 
considered by the local investigator to be clini-
cally significant) occurred more frequently in the 
amodiaquine–artesunate group (1.5%) than in 
the other treatment groups (range, 0.6 to 0.8%). 
There were no significant differences in the 
laboratory safety values among the treatment 
groups.
Outcome of Pregnancy
There were 13 miscarriages (1 miscarriage in the 
artemether–lumefantrine group and 4 in each of 
the other three groups). There were 78 stillbirths 
overall, with 16 stillbirths occurring in 856 
births (1.9%) in the artemether–lumefantrine 
group, 17 in 815 (2.1%) in the amodiaquine–
Variable
Artemether– 
Lumefantrine 
(N = 880)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 853)
Mefloquine– 
Artesunate 
(N = 848)
Intention-to-treat analysis
PCR-adjusted
No. of patients 807 776 744 753
Rate — % (95% CI) 94.2 (92.3–954.6) 96.9 (95.4–97.9) 98.0 (96.7–98.8) 95.5 (93.8–96.8)
PCR-unadjusted
No. of patients 830 791 759 770
Rate — % (95% CI) 52.5 (49.1–55.9) 81.2 (78.3–83.7) 86.0 (83.4–88.3) 72.3 (69.1–73.4)
*  CI denotes confidence interval.
†  Early treatment failure was defined as one of the following: the development of danger signs or severe malaria or worsening of clinical con-
ditions on day 0, 1, 2, or 3 in the presence of parasitemia; parasitemia on day 3 that was the same as or greater than the count on day 0;  
or parasitemia on day 3 and fever (axillary temperature, ≥37.5°C). Late clinical failure was defined as the either the development of danger 
signs or severe malaria or worsening of clinical conditions on any day after day 3 in the presence of parasitemia, without the patient having 
previously met any of the criteria for early treatment failure, or the presence of parasitemia and fever on any day after day 3, without the pa-
tient having previously met the criteria for early treatment failure. Late parasitologic failure was defined as the presence of parasitemia after 
day 3 and an axillary temperature of less than 37.5°C, without the patient having previously met any of the criteria of early treatment failure 
or late clinical failure. An adequate clinical and parasitologic response was defined as the absence of parasitemia at the end of the follow-up 
period (day 63), regardless of the axillary temperature, without the patient having previously met any of the criteria of early treatment failure 
or late clinical or parasitologic failure. In the polymerase-chain-reaction (PCR)–adjusted estimates, patients with late asexual-parasite reap-
pearance (with or without fever) were considered to have had an adequate clinical and parasitologic response if the PCR analysis showed a 
new infection rather than a recrudescence.
‡  The one death that occurred during the trial was not considered by the investigators to be related to malaria or to treatment (probably due 
to meningitis).
§  In the estimation of the PCR-adjusted cure rate, only recurrent infections that were shown to be the same as those before treatment were 
considered to be treatment failures. Conversely, for the estimation of the PCR-unadjusted cure rate, all recurrent infections were considered 
to be treatment failures. If the difference in the true (PCR-adjusted) cure rates was less than 5 percentage points, the treatments were con-
sidered to be therapeutically equivalent. Treatment success rates according to country are provided in Tables S7 (per-protocol analysis) and 
S8 (intention-to-treat analysis) in the Supplementary Appendix.
Table 2. (Continued.)
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artesunate group, 22 in 818 (2.7%) in the dihy-
droartemisinin–piperaquine group, and 23 in 821 
(2.8%) in the mefloquine–artesunate group. The 
proportion of live births did not differ signifi-
cantly among the treatment groups (P = 0.85). 
The percentage of preterm babies, as determined 
by the total Ballard score, was 10.2% in the arte-
mether–lumefantrine group, 3.4% in the amo-
diaquine–artesunate group, 9.5% in the dihydro-
artemisinin–piperaquine group, and 7.7% in the 
mefloquine–artesunate group (P = 0.64). A total 
of 44 congenital malformations were observed, 
with 17 occurring in 832 newborns (2.0%) in the 
artemether–lumefantrine group, 8 in 776 (1%) in 
the amodiaquine–artesunate group, 6 in 767 
(0.8%) in the dihydroartemisinin–piperaquine 
group, and 13 in 780 (1.7%) in the mefloquine–
artesunate group.
Discussion
The PCR-adjusted cure rates were in the range of 
94.8 to 99.2% for all four artemisinin-based 
combination therapies, and the differences among 
them were within the prespecified equivalence 
margin of 5 percentage points. The high success 
Figure 2. Differences in PCR-Adjusted and PCR-Unadjusted Treatment Success Rates at Day 63, According to Pairwise Analysis  
and Country.
In the estimation of the polymerase-chain-reaction (PCR)–adjusted cure rate, only recurrent infections that were shown by means of 
 genotyping to be the same infections as those before treatment (recrudescences) were considered to be treatment failures. Conversely, 
for the estimation of the PCR-unadjusted cure rate, all recurrent infections were considered to be treatment failures. A positive value in 
the difference reflects a higher cure rate in the treatment listed first. If the difference in the cure rates was less than 5 percentage points 
(red lines), the treatments were considered to be therapeutically equivalent. Dashed horizontal lines indicate the 95% confidence inter-
vals for the comparisons of treatment groups within a single country; solid horizontal lines are used for comparisons of total data from 
two countries.
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rates are remarkable given the long follow-up 
period, which was 3 weeks longer than the 
6 weeks recommended by the WHO. Neverthe-
less, the cure rates in the artemether–lumefan-
trine group were significantly lower than those 
in the groups that received the other artemisinin-
based combination therapies, which had similar 
high efficacy. In a previous trial in Uganda, the 
efficacy of artemether–lumefantrine (until day 42) 
during pregnancy was 99.3%.12 The longer fol-
low-up until day 63 in our trial cannot explain 
the lower cure rates in our trial than in the 
Uganda trial, because most treatment failures 
occurred between day 28 and day 42 (Fig. S1 in 
the Supplementary Appendix). The efficacy of 
artemether–lumefantrine was low (82%) among 
pregnant women at the Thai–Burmese border,13 
a finding that was attributed to low drug con-
centrations and low antimalarial immunity.14,15 
In Uganda, the plasma concentration of lume-
fantrine was 27% lower in pregnant women than 
in nonpregnant women,16 which suggests that the 
high efficacy of artemether–lumefantrine was 
probably due to the higher background immu-
nity in Uganda than in Thailand. In our trial, 
artemether–lumefantrine was tested in three 
countries with a high risk of malaria infection 
(owing to the high intensity of malaria trans-
mission), so the background immunity among 
recruited pregnant women was probably high.
Patients treated with artemether–lumefantrine 
had the highest rate of reinfection and the short-
est time to reinfection. The duration of post-
treatment prophylaxis is an important factor in 
the choice of antimalarial drugs, especially in 
areas with a high risk of infection. Lumefantrine 
has the shortest elimination half-life,17 followed 
by mefloquine,18 amodiaquine,19 and then piper-
aquine.20
The efficacy of artemether–lumefantrine was 
relatively low in Burkina Faso (93.2%). This was 
the same trial site at which the efficacy of arte-
mether–lumefantrine among children with ma-
laria was the lowest (90.2%) among trial sites in 
sub-Saharan Africa.21 The sites in Burkina Faso 
also had the highest intensity of transmission, 
as suggested by the high rates of reinfection 
observed in all the treatment groups (Table S7 in 
the Supplementary Appendix). This high intensity 
of transmission may influence the interpretation 
of the genotyping results, with the risk that new 
infections may be misclassified as recrudes-
cences.22 In our trial, capillary electrophoresis, a 
technique that can minimize misclassification,23 
was used for MSP2 genotyping. In addition, 
transmission intensity may influence the indi-
vidual treatment cure rates but not the risk dif-
ference between treatments.23
There was no significant difference in birth 
outcomes among the treatment groups. The 
mean birth weight as well as the proportion of 
miscarriages, stillbirths, preterm deliveries, and 
congenital malformations were similar among 
the groups.
Fewer adverse events were seen in the arte-
mether–lumefantrine group and the dihydroar-
temisinin–piperaquine group than in the other 
two groups.15,20,24 Approximately half the adverse 
events in the amodiaquine–artesunate group and 
mefloquine–artesunate group were considered 
by the investigator to be related to treatment. 
Asthenia was the most common event in the 
amodiaquine–artesunate group, followed by diz-
ziness; both these events may be related to low 
blood pressure and pulse rate. Asthenia was 
more common in the amodiaquine–artesunate 
group than in the other three groups. Nausea or 
vomiting was also relatively common. General 
weakness, vomiting, dizziness, and nausea were 
the most commonly reported adverse events 
among pregnant women in Ghana who were 
treated with amodiaquine.25,26 Dizziness was the 
most frequent treatment-related adverse event in 
the mefloquine–artesunate group, followed by 
vomiting, nausea, and asthenia. The association 
between mefloquine and dizziness has already 
been reported; more than 30% of pregnant 
women who were treated with mefloquine mono-
therapy at a dose of 15 mg per kilogram of body 
weight reported dizziness, but the occurrence 
decreased after subsequent doses.27 Because this 
trial was an open-label trial, determination of 
the cause of adverse events may have been influ-
enced by the knowledge of the treatment given.28 
Three women had behavior changes soon after 
the onset of treatment, one in the mefloquine–
artesunate group and two in the amodiaquine–
artesunate group. Mefloquine use has been as-
sociated with neuropsychiatric adverse events,29 
a phenomenon that has also been described for 
4-aminoquinolines.6
In conclusion, artemether–lumefantrine was 
associated with the fewest adverse effects and 
with acceptable cure rates but provided the short-
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on June 27, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 374;10 nejm.org March 10, 2016924
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Event
Artemether– 
Lumefantrine 
(N = 881)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 855)
Mefloquine– 
Artesunate 
(N = 850)
percent of patients
Any serious adverse event during 63 days 
of follow-up
0.7 2.6 2.1 2.9
Mild 0 0.2 0.2 0.5
Moderate 0.2 1.3 1.2 1.5
Severe 0.2 0.7 0.5 0.5
Life-threatening 0.2 0.4 0.2 0.5
Specific serious adverse event during 63 days 
of follow-up
Blood disorder 0 0.7 0.2 0
Moderate 0 0.2 0 0
Severe 0 0.4 0.2 0
Life-threatening 0 0.1 0 0
Moderate abdominal pain 0 0.2 0 0.1
Severe diarrhea 0.1 0 0 0
Vomiting 0 0 0 0.2
Moderate 0 0 0 0.1
Severe 0 0 0 0.1
Malaise 0 0.2 0 0.1
Mild 0 0.2 0 0
Moderate 0 0 0 0.1
Moderate adverse drug reaction 0 0 0.1 0
Infection 0.5 1.0 1.1 1.5
Mild 0 0 0.2 0.2
Moderate 0.2 0.8 0.8 0.9
Severe 0 0.1 0 0.2
Life-threatening 0.2 0 0 0.1
Complications of pregnancy and delivery 0.1 0.5 0.5 0.7
Mild 0 0.1 0 0
Moderate 0 0 0.1 0.2
Severe 0.1 0.1 0.1 0.1
Life-threatening 0 0.2 0.2 0.4
Mild asthma 0 0 0 0.1
Any adverse event during 63 days of follow-up 72.8 79.0 70.4 84.9
Mild 54.4 56.7 59.1 68.8
Moderate 18.2 21.5 11.1 15.2
Severe 0.1 0.7 0.2 0.8
Life-threatening 0.1 0.1 0 0.1
Any event during first 7 days 24.3 59.5 34.2 60.7
Table 3. Safety Outcomes.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on June 27, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 374;10 nejm.org March 10, 2016 925
Artemisinin-Based Treatments in Pregnant Women with Malaria
Event
Artemether– 
Lumefantrine 
(N = 881)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 855)
Mefloquine– 
Artesunate 
(N = 850)
percent of patients
Any drug-related event 11.5 48.5 20.6 50.6
Mild 10.1 37.1 18.4 41.9
Moderate 1.2 11.2 2.1 8.2
Severe 0.1 0.2 0.1 0.5
Specific drug-related adverse event*
Abdominal pain 2.7 7.1 2.1 5.3
Mild 2.2 6.3 2.0 4.2
Moderate 0.6 0.8 0.1 1.1
Asthenia 1.8 26.6 6.8 14.2
Mild 1.6 16.7 6.0 10.4
Moderate 0.2 9.9 0.8 3.5
Severe 0 0 0 0.4
Decreased appetite 0.3 8.2 2.1 7.1
Mild 0.3 7.1 2.0 6.6
Moderate 0 1.1 0.1 0.5
Dizziness 1.2 23.5 1.6 30.6
Mild 1.2 16.2 1.4 24.2
Moderate 0 7.2 0.2 6.2
Severe 0 0.1 0 0.1
Headache 4.3 6.3 5.1 7.5
Mild 3.7 4.8 4.4 6.6
Moderate 0.6 1.5 0.7 0.9
Musculoskeletal pain 0.8 7.2 2.6 4.5
Mild 0.8 5.8 2.3 3.2
Moderate 0 1.4 0.2 1.2
Severe 0 0 0 0.1
Nausea 0.9 11.5 4.0 13.9
Mild 0.9 10.6 3.7 12.6
Moderate 0 1.0 0.2 1.3
Vomiting 0.9 15.9 5.7 18.9
Mild 0.8 12.5 5.1 13.5
Moderate 0.1 3.4 0.6 5.4
Abnormality in vital sign during treatment†
Pulse rate <60 beats/min 1.1 2.1 1.6 1.5
Diastolic blood pressure <50 mm Hg 8.4 15.1 7.7 4.7
Systolic blood pressure <90 mm Hg 5.1 12.2 6.3 4.1
*  The specific drug-related adverse events reported here were those that occurred in more than 5% of the patients in at least one treatment group.
†  Abnormality in vital signs during treatment was assessed during days 1, 2, and 3; the percentage of patients shown is the percentage of 
those with an abnormality on any of these days.
Table 3. (Continued.)
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est post-treatment prophylaxis. Dihydroartemis-
inin–piperaquine had the best efficacy and an 
acceptable safety profile.
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